Abstract

The complex interplay between hormonal shifts, vitamin D insufficiency, and osteoporosis. Hormones such as estrogen, testosterone, parathyroid hormone, cortisol, thyroid hormones, and growth hormone all play important roles in bone density and turnover. Changes in their levels, whether due to normal aging or medical disorders, can disturb bone remodelling and raise the risk of osteoporosis. Furthermore, vitamin D insufficiency heightens the risk by reducing calcium absorption and bone mineralization. Estrogen and vitamin D deficits increase bone loss, especially in postmenopausal women. Proactive treatment techniques, including hormone replacement therapy, vitamin D supplements, and lifestyle changes, are critical for maintaining good bone health and lowering the risk of fracture. Understanding and addressing these factors are paramount for preventing osteoporosis and its associated complications, especially in vulnerable populations.

Keywords: Vitamin D, osteoporosis, and estrogen

Introduction

Osteoporosis is a woman’s age-related trouble which causes bone weakness and fracture. The correlation between vitamin D deficiency with osteoporosis is particularly relevant for females after menopause because this population is at an increased risk of both conditions (Hejazi et al.,2020). Vitamin D is important for preserving calcium homeostasis also improving bone health. The active 1,25-Dihydroxy vitamin D, [25(OH)D] metabolite binds to a specific hormone receptor which leads to increased absorption of a intestinal calcium and regulates bone turnover ( Fleet ,2022). Low vitamin D levels cause changes in calcium and phosphorus balance, secondary hyperparathyroidism, osteoporosis and increased risk of fracture. Severe levels of vitamin D deficiency lead to bone mineralization also osteomalacia. The normal process of evaluating vitamin D is by determining the serum [25(OH)D] vitamin D level of the main circulating metabolite ( De Martinis et al.,2021).  Overall, addressing vitamin D deficiency in postmenopausal women is essential not only for preventing osteoporosis but also for promoting overall health and well-being (Ferrillo et al.,2022). This review paper discusses the vitamin D deficiency impact and osteoporosis on females after menopause.

Osteoporosis

             Osteoporosis is a medicinal state characterized by the bones weakening, resulting in reduced bone density also improved fracture weakness. This happens because the bone quality with density is diminished causing bones brittle and fragile (Enitan et al.,2023). Osteoporosis often develops silently, without obvious symptoms until a fracture occurs, usually in the hip, back or wrist. It is extraordinary in big persons, mainly postmenopausal women, although it can influence all ages people and genders (Anam and Insogna,2021). Various factors, including genetics, hormonal modification and daily life options, contribute to osteoporosis growth. Preventive measures and treatments aim to sluggish bone loss and also decrease the fracture risk (Amin et al.,2023 (.

        Osteoporosis occurs when there is an inequity in the natural bone remodeling process. Our bones are always being busted and rebuilt, but in osteoporosis, the bone resorption rate goes over bone construction. Several factors can contribute to this imbalance, including hormonal changes, nutritional deficiencies, ageing, and certain medications ) Lewis et al.,2022 ).

    The primary concern with osteoporosis is the increased fracture risk, especially in weight-bearing hip bones, spine and wrist. Hip bone fractures can be particularly critical and may lead to long-term disability or even death in some cases ( Wu et al.,2019 ). Vertebral (spinal) fractures can illustrated in back pain, loss of height and poor posture. Osteoporosis is often diagnosed through the BMD test, Bone Mineral Density, which estimates the bone density at different body sites, typically the hip and spine. Other diagnostic tools may include X-rays, blood tests to check for underlying conditions, and assessment of fracture risk(  Ponzano et al.,2023 ).

Risk Factors of Osteoporosis

       Osteoporosis becomes more common as individuals age. Women, especially after menopause, are at a higher risk [12]. Moreover, a family history of osteoporosis increases your risk and decreases the levels of estrogen in women also the low levels of testosterone in men may contribute. Insufficient Ca and vitamin D take may weaken bones. As well as, lack of physical activity, smoking, heavy alcohol drinking and a routine lifestyle can enhance the risk( Rozenberg et al.,2020  ).

Prevention and Treatment of Osteoporosis

        The strategies for osteoporosis prevention and management involve ( Gregson et al.,2022 ).

   – Sufficient Ca with vitamin D taken via diet or supplements.

   – Accepted weight-bearing plus strength-training exercises to strengthen bones and improve balance.

   – Lifestyle changes such as quitting smoking and moderating alcohol consumption.

   – Medications, such as bisphosphonates, hormone therapy, or newer biologic drugs, can help reduce bone loss and the risk of fractures.

   – Fall prevention strategies to avoid accidents that could lead to fractures.

Osteoporosis and Gender

        Osteoporosis is a bone disease which men and women suffer from, but it is more common in women, especially postmenopausal women. One of the primary reasons is the hormonal changes associated with menopause ( Aayushi and Kekatpure,2022). Estrogen hormone works to maintain bone density which considerably decreases during menopause and leads to rapid bone loss (Gosset et al.,2021). Women usually have less peak bone mass; which is the highest amount of bone tissue individuals attain compared to men, typically in their late 20s or early 30s. Lower peak bone mass puts women at a disadvantage when it comes to maintaining bone density in later life. Postmenopausal women are particularly susceptible to fractures of the hip, spine and wrist. These fractures can have serious consequences, including loss of mobility and independence ( Xue et al.,2020).

         Although osteoporosis is less common than in women, this disease in men poses an important health problem. It is often underdiagnosed and undertreated in men ( Rinonapoli et al.,2021  ). Men typically have high peak bone mass also a lower bone loss rate than women, which partially explains the lower prevalence. In men. osteoporosis risk factors include age, family history, testosterone levels, definite medicine and medical. While men have a lesser osteoporosis-related risk of fractures than women, when fractures occur in men with osteoporosis, they tend to have worse outcomes, including higher mortality rates (Vescini et al.,2021  ).

        Osteoporosis in both men and women is detected through reduced bone density also increased fracture susceptibility. The fundamental mechanism of bone loss involves a difference between bone resorption and formation that is similar between genders ( Eirini et al.,2022  ).

The principles of prevention and management are similar for both genders and include sufficient Ca and vitamin D take, weight-bearing training, daily life modifications (e.g., quitting smoking, moderating alcohol consumption), and, in some cases, medications to reduce bone loss also fracture risk (Adejuyigbe et al.,2023   ).

The osteoporosis and aging relation

        Aging and osteoporosis are closely related, and osteoporosis is often considered an age-related condition. Aging contributes to the development of osteoporosis: Throughout life, bones undergo a continuous remodeling process, old bone tissue is broken and other new bones are formed (Pignolo et al.,2021 ). In young adulthood, bone formation generally exceeds bone resorption, leading to an increased in both bone mass and strength. However, as individuals age, this balance shifts. Additionally, Peak bone mass is defined as the highest amount of bone tissue a person attains, typically reached by the late 20s or early 30s. After this point, bone density gradually starts to decline naturally with age. This decline is more marked in women past menopause owing to the reduction in estrogen limits, which have a key role in maintaining bone density ( Chandra and Rajawat, 2021 ).

     Beyond middle age (around 50 years old for women and somewhat later for men), bone loss tends to accelerate. This loss of bone density is more rapid in certain areas, such as the spine and hip, making these bones particularly susceptible to fractures (Aspray snd Hill, 2019 ). Ageing can lead to changes in the bone’s structure, making it less dense and more porous. This structural deterioration weakens the bones, making them more prone to fractures. In postmenopausal women, the decline in estrogen production can result in a significant reduction in bone density (Pinheiro et al.,2020). Estrogen has an essential role in preserving bone health by preventing bone resorption. Also, men have regularly decreased testosterone limits with age, which can participate in bone loss. As people age, they may become less physically active, leading to decreased muscle strength and bone-loading activities. Weight-bearing exercises and resistance training are essential for maintaining bone density, and reduced physical activity can exacerbate bone loss (Hadji et al.,2019  ).

      Older adults may have dietary habits that are less conducive to maintaining bone health. Poor nutrition, insufficient Ca and vitamin D intake, and certain medications can further contribute to the risk of osteoporosis  (Bhattarai et al.,2020 ).

     Osteoporosis is often considered a “silent” condition because it develops gradually over time. The cumulative effects of age-linked bone loss, especially when joint with other risk factors, increase the likelihood of developing osteoporosis and experiencing fractures in life ) Roy,2021).

The Relationship Between Hormonal Changes and Osteoporosis

       Hormones have a central role in maintaining the density and strength of bone. Several hormones influence bone health, and alterations in their levels can contribute to osteoporosis development ( Cannarella et al.,2019 ). Estrogen is a hormone predominantly associated with females, although men also have small amounts of it. In women, estrogen helps maintain bone density by inhibiting bone resorption (the breakdown of bone tissue) (Cheng et al.,2022). However, during menopause, which typically occurs in the late 40s or early 50s, a woman’s ovaries create less estrogen. This hormonal shift leads to accelerated bone loss, making postmenopausal women particularly at risk for osteoporosis. Hormone replacement therapy (HRT) with estrogen and sometimes progestin may be prescribed to reduce bone loss in postmenopausal women (Lu and Tian ,2023).

     Testosterone is the essential male sex hormone, and it is also found in females, albeit in lesser amounts. In men, testosterone helps build and maintain bone density throughout life. As men age, their testosterone levels gradually decrease, which can contribute to a gradual reduction in bone density. Low testosterone limits are related to the increased osteoporosis risk in older men (Shigehara et al.,2021 ).

     Parathyroid Hormone, PTH is formed in the parathyroid glands which have an essential role in modifiable Ca limits in the body. When blood Ca limits drop, PTH clarifies the Ca release from bones to preserve normal blood calcium levels ( Jubair et al.,2021). If PTH levels are consistently elevated due to a medical condition like primary hyperparathyroidism, it can lead to excessive bone resorption and weaken bones( Lombardi et al.,2020).

Calcitonin is a hormone produced by the thyroid gland. Its role in bone health is to inhibit bone resorption by osteoclasts (cells that break down bone tissue). While calcitonin can help regulate bone turnover, its role in preventing osteoporosis is not as prominent as other hormones  (Srinivasan et al.,2020).

    Cortisol (Glucocorticoids) a hormone produced by the adrenal glands, is important for various bodily functions, including immune response and metabolism. However, excessive levels of glucocorticoids, whether produced naturally in response to stress or taken as medications (e.g., prednisone), can lead to bone loss. This condition is known as glucocorticoid-induced osteoporosis (Al-Rawaf et al.,2021  ).

        Thyroid hormones, produced by the thyroid gland, regulate metabolism. An overactive thyroid (hyperthyroidism) can accelerate bone turnover and lead to bone loss, while an underactive thyroid (hypothyroidism) can also affect bone health (Lademann et al.,2020 ).

    Growth Hormone, GH formed by the pituitary gland, stimulates bone growth through babyhood and youth. Deficiencies in growth hormone in children can result in reduced bone growth and lower peak bone mass, this may increase the osteoporosis risk in later life   (Mazziotti et al.,2022   ).

        The relationship between hormonal changes and osteoporosis underscores the importance of hormonal balance for maintaining optimal bone density ( Tremollieres ,2019). When hormonal changes occur due to natural ageing, medical conditions, or treatments, they can disturb the bone slight balance remodelling also contributes to bone loss. Managing hormonal imbalances through medications or lifestyle modifications can help mitigate the risk of osteoporosis and its complications ( Rinonapoli et al.,2021 ).

The Vitamin D Deficiency and Osteoporosis Relation

       Vitamin D is essential for dietary Ca absorption in the little intestine. Calcium is a vital element for building and maintaining bone density. When there is insufficient vitamin D, the body struggles to absorb an adequate amount of calcium from the diet, even if dietary calcium intake is sufficient. This results in a negative calcium balance, where more calcium is being removed from bones than absorbed, leading to weakened bones over time ( Wawrzyniak and Suliburska,2021  ).

     Vitamin D helps regulate the deposition of minerals, particularly calcium and phosphorus, into the bone matrix. Adequate vitamin D is necessary to ensure that calcium and other minerals are properly incorporated into the bone structure. In vitamin D deficiency, bone mineralization becomes impaired, which can lead to brittle and porous bones that are more susceptible to fractures(  Christakos et al.,2021 ).

       Vitamin D has a function in controlling bone resorption, the old bone tissue is broken and replaced with a new one. When there is a deficiency of vitamin D, bone resorption can become more active, leading to a net bone density loss over time ( Charoenngam et al.,2019).

      Vitamin D controls the parathyroid hormone PTH, which controls calcium limits in the blood. When blood Ca limits are decreased, PTH is released to stimulate the Ca release from bones to maintain normal blood Ca levels. In the presence of vitamin D deficiency, PTH levels can become elevated, further promoting bone resorption. Vitamin D deficiency can lead to muscle weakness and impaired balance and increases the fall risk and related fractures(Bhattarai et al.,2020 ).

        Deficiency of vitamin D can disrupt the delicate balance of bone remodeling by impairing calcium absorption, bone mineralization, and muscle strength, while also increasing the activity of bone-resorbing cells. All of these factors contribute to a high risk of developing osteoporosis and experiencing fractures, particularly in older adults (De Martinis et al.,2021).

      Preventing and managing vitamin D deficiency is an important component of osteoporosis prevention and treatment. This can often be achieved through dietary changes, supplements when necessary, sensible sun exposure, and healthcare provider guidance to ensure adequate vitamin D levels and optimal bone health(Bhattarai et al.,2020 ).

      The majority of individuals in the globe get at least some of their vitamin D from sunlight. Type B Ultraviolet radiation UVB with a wavelength of about 290–320 nm go through exposed skin and changes cutaneous 7-dehydrocholesterol to pre-vitamin D3, which in revolve as vitamin D3. The factors that affect exposure to UV radiation and vitamin D production include; season, daytime, the day length, dark cover, smoke, melanin content of skin and sunscreen ( Keogh and Clifton,2013  ). Older people also dark-skinned people are less capable of making vitamin D from UVB sunlight, this ray does not go through a window, so contact with sunshine inside a glass does not create vitamin D ( DeLuccia et al.,2021 ).

     The variables that influence UV ray exposure, personal reactivity, and doubts about the quantity of sun contact necessary to sustain sufficient vitamin D limits generate recommendations on the appropriate period of exposure to sunlight to obtain a necessary amount of vitamin D synthesis. Some vitamin D specialist organisations and authorities, for example, advise that sunlight exposure for 5-30 minutes, if possible between 10 a.m. and 4 p.m., of the entire face, arms and leg with no sunblock daily or as a minimum twice a week, generally results in adequate vitamin D synthesis. It is also useful to use marketable tanning booths that produce 2% to 6% UVB ray (Jou and Tomecki ,2014 ).

     But even with the sunlight significance for vitamin D creation, be careful not to expose the skin to sunlight also UV rays from tanning beds. UV rays are a carcinogen, so UV exposure is the major avoidable skin cancer source. To decrease the chance of skin cancer, national organisations recommend adopting photoprotective measures, such as sunscreen with a sun protection factor and, an SPF of 15 or larger when individuals are exposed to the sun (Abdullah et al.,2021). Sunscreens of an SPF of 8 or higher are used to avoid UV radiation that produces vitamin D. In reality, most people do not apply sufficient sunscreen, cover up their sun-exposure skin, or reuse sunblock frequently. Even with normal sunscreen levels, their skin presumably synthesizes some vitamin D(Perugini et al.,2019   ).

      A deficiency or dysfunction of vitamin D receptors (VDRs) can significantly impact bone health and add to osteoporosis growth or exacerbation (Ahi et al.,2020).  VDRs are proteins found in various tissues throughout the body, including the bone, and play a crucial role in mediating the vitamin D effects (Di Bari et al.,2021). The first of the primary VDR functions is to mediate the action of vitamin D in the intestines, where it enhances the absorption of dietary Ca (Fleet,2022). If there is a deficiency or dysfunction of VDRs, this calcium absorption process is compromised, leading to reduced calcium availability for bone mineralization ( Christakos et al.,2020  ). VDRs are also present in bone cells, including osteoblasts, cells of bone formation osteoclasts cells of bone resorption. A deficiency or dysfunction of VDRs can disrupt the balance between bone forming and resorbing, potentially leading to an imbalance that favors bone resorption (Sharma et al.,2021). This imbalance can be illustrated in net bone loss and reduced bone density, characteristic of osteoporosis. They have a function in regulating the suitable mineralization of bone tissue. When VDRs are not functioning correctly, it can hinder the deposition of Ca plus other elements into the bone matrix, making bones less dense and more susceptible to fractures ( Anesi et al.,2019). It’s important to note that VDR dysfunction or deficiency is relatively rare, and most cases of osteoporosis are not directly linked to VDR issues. Instead, osteoporosis is often associated with such features; as ageing, hormonal modification, especially in postmenopausal women, insufficient Ca and vitamin D intake, inactive lifestyle, and other genetic and lifestyle-related factor( Marozik et al.,2021 ).

The relation between deficiency of vitamin D with Estrogen and Osteoporosis

      Estrogen and vitamin D both play critical roles in bone health, and their deficiency can contribute to osteoporosis development also progression (Hassan et al.,2021 ). Estrogen is a hormone primarily produced by the ovaries in women. Before menopause, estrogen has a protective function in bone health. It assists in reducing osteoclast activity, which is responsible for bone tissue resorption ( Anagnostis et al.,2021 ). As a result, estrogen helps to maintain bone density and prevents excessive bone loss. Estrogen joins with estrogen receptors to support the phase of osteoprotegerin (OPG), and to repress the nuclear factor-κβ ligand, RANKL action, so reducing osteoclast formation also resorptive bone activity. It helps regulate the activity of osteoclasts, specialized cells responsible for bone resorption. In the presence of estrogen, osteoclast activity is reduced, guide to a decrease in bone breakdown. This inhibition of osteoclasts helps to maintain bone density( Cheng et al.,2022).

       Estrogen suppresses the release of parathyroid hormone (PTH) in the parathyroid glands. PTH have a function in regulating the blood Ca levels (Eltayef ,2022 ). High PTH levels can lead to increased bone resorption, so the suppression of PTH by estrogen helps reduce bone breakdown. It helps indirectly maintain calcium levels in the bloodstream. By inhibiting bone resorption and promoting bone formation, estrogen helps ensure that calcium is deposited on the bone matrix rather than being liberated into the bloodstream    ( Wawrzyniak and Balawender,2022).

     After menopause, estrogen levels significantly decline because the ovaries produce less estrogen. This hormonal shift results in a state of estrogen deficiency, which is a chief risk parameter for osteoporosis in postmenopausal women. With reduced estrogen, bone resorption becomes more active, leading to accelerated bone loss, weakened bones, also an increased fracture risk )Beltz and Moser,2020)

    Estrogen deficiency after menopause can affect vitamin D metabolism and reduce its effectiveness in maintaining Ca balance and bone health. Conversely, vitamin D deficiency can aggravate the bone defeat related to estrogen deficiency because it impairs calcium absorption and bone mineralization (Huang et al.,2019).

    In summary, both estrogen deficiency, especially after menopause, and vitamin D deficiency are significant osteoporosis risk factors. They each contribute to bone loss through different mechanisms, but their combined impact can be particularly detrimental to bone health ( Cheng et al.,2022). Postmenopausal women are often at a higher risk because they may experience both estrogen and vitamin D deficiencies simultaneously. Preventing and managing osteoporosis in this population typically involves strategies such as hormone replacement therapy (HRT) to address estrogen deficiency and ensure adequate vitamin D intake through diet, supplements, and safe sun exposure ) Askin et al.,2019).

Osteoblasts and Osteoclasts

    Osteoblasts are specialized cells in the body which are dependable for bone formation, a process identified as osteogenesis or osteogenesis (Setiawati and Rahardjo,2019). They are a critical component of the bone remodelling cycle, which involves the constant bone tissue turnover to maintain bone strength, repair micro-damage, and adapt bones to mechanical stresses )Mizoguchi and Ono, 2020).Osteoblasts are bone-building cells that create also deposit the organic components of bone tissue, including collagen fibers. These collagen fibers provide the framework for new bone formation. They also have a job in mineralization, where calcium and phosphate ions are deposited onto the collagen framework to create the hardened, mineralized matrix of bone tissue. This process gives bones their strength and rigidity. Osteoblasts produce various proteins and molecules that are essential for bone formation. These include osteocalcin, osteopontin, and bone sialoprotein, among others (Toosi and Behravan, 2020).

     Osteoblasts work in coordination with osteoclasts, which are responsible for bone resorption (breakdown), to maintain bone homeostasis. They are influenced by different factors, including hormones like parathyroid hormone (PTH) also calcitonin, as well as growth factors and cytokines. For example, PTH stimulates osteoblasts to produce molecules that enhance bone resorption by osteoclasts while also promoting bone formation(Sims and Martin,2020 ).

       Osteoblasts have a crucial function in bone repair and regeneration. After an injury or fracture, osteoblasts are recruited to the damaged area to leave down new bone, helping to mend the bone and restore its strength. Some osteoblasts fixed within the bone matrix then make a differentiation into a more mature cell type called osteocytes. Osteocytes are the main cells which are dependable for monitoring and maintaining bone health. They are interconnected within the bone and play a function in sensing mechanical stress also modifiable bone remodeling ( Chang et al.,2019).

       Vitamin D deficiency may influence the production of osteocalcin, a protein produced by osteoblasts that is essential for proper bone mineralization. When osteocalcin levels are low owing to vitamin D deficiency, bone formation may be compromised. Some studies suggest that vitamin D deficiency can directly affect osteoblast function, reducing their ability to form new bone tissue. This inhibition can guide to reduced bone formation plus potential bone loss over time. van Driel and van Leeuwen ,2023).

          Osteoclasts are large, multinucleated cells, meaning they have multiple nuclei within a single cell. This multi-nucleation allows them to efficiently resorb bone tissue. They are specialized cells in the body responsible for the resorption or breakdown of bone tissue (Takito and Nakamura, 2020). They are a vital part of the bone remodelling procedure, which includes continuous old or damaged bone removal also new bone tissue formation. Osteoclasts play an essential part in continuing the balance among bone resorption also formation, ensuring that bones remain healthy and function properly( Ahmadzadeh et al.,2022  ).

        Osteoclasts attach themselves to the bone tissue surface and produce enzymes also acids which dissolve the minerals mainly composed of Ca and phosphate and break down the organic bone components, for example, collagen. This process liberates Ca with other elements from the bone into the bloodstream, regulating blood calcium levels [68]. They are involved in the bone remodelling cycle, which includes the old or damaged bone removal, and resorption phase) as well as the subsequent new bone tissue formation via osteoblasts, and bone-building cells. This continuous remodelling process helps repair micro-damage in bones, adapt bones to mechanical stresses, and maintain bone strength and integrity ( Søe et al.,2021). The activity of osteoclasts is closely controlled to keep the proper balance between bone resorption and formation. Various factors, including hormones, for example, parathyroid hormone also calcitonin, cytokines, growth features, the effect of the activity of osteoclasts and the overall bone remodelling process (Al‐Bari and  Al Mamun,2021).

      Imbalances in the activity of osteoclasts can lead to bone disorders. Excessive bone resorption or overactive osteoclasts can result in conditions like osteoporosis, where bones become weak and brittle due to increased bone loss. On the other hand, reduced osteoclast activity can lead to great bone formation and situations like osteopetrosis, where bones turn to be unusually dense and prone to fractures ( Chang et al.,2019   ).

     Vitamin D deficiency can increase the parathyroid hormone, PTH secretion by the parathyroid glands. Elevated PTH levels stimulate osteoclasts to become more active, leading to increased bone resorption( Al-Suhaimi et al.,2022 ) This process, known as secondary hyperparathyroidism, results from the body’s attempt to maintain normal blood calcium levels in the face of decreased calcium absorption due to vitamin D deficiency( Abed et al.,2020 ). It can lead to net bone resorption increases by osteoclasts also a reduction in bone density. This takes place because the lack of vitamin D impairs calcium absorption, making the body more reliant on releasing Ca from bone tissue to maintain Ca blood limits (Charoenngam et al.,2019). Prolonged vitamin D deficiency can result in weakened bones due to excessive bone resorption by osteoclasts. These weakened bones may become brittle and porous, increasing the fracture risk. In summary, vitamin D deficiency can indirectly influence osteoclast activity by causing disruptions in calcium homeostasis and hormonal regulation. This disruption can lead to increased bone resorption and the potential for bone loss, particularly if the deficiency is severe or prolonged (Sobh et al.,2022 ).

Bone loss mechanism in menopausal women with vitamin D and Estrogen deficiency

     Before menopause, estrogen has a protective effect on bones by inhibiting osteoclast activity, cells dependable for breaking bone tissue, and resorption. When estrogen levels drop significantly during menopause, this protective effect diminishes, leading to increased bone resorption. Estrogen deficiency disrupts the normal balance between bone resorption also formation (Rizzoli and Biver, 2020). With less inhibition of osteoclasts, bone resorption becomes more active, while bone formation may be impaired. This skewed bone remodeling process leads to a net bone density loss of more time. Estrogen has a function in preserving bone tissue quality. Its deficiency can result in structural changes, such as decreased bone density also alterations in the bone microarchitecture. These changes make bones more fragile and prone to fracture( Ito et al.,2021).

     In the presence of vitamin D deficiency, the body’s capability to absorb Ca is compromised. This leads to insufficient calcium levels in the bloodstream, triggering a compensatory mechanism. In response to low blood Ca limits, the glands of the parathyroid make parathyroid hormone (PTH) ( Dominguez et al.,2021). Elevated PTH levels stimulate the calcium release from bones to keep normal Ca blood limits. This route, known as secondary hyperparathyroidism, increases bone resorption and weakens bones. Vitamin D is required for proper bone tissue mineralization (Allgrove and  Cheung, 2019).  In vitamin D deficiency, the mineralization process is disrupted, resulting in the formation of brittle and porous bones. These bones are more susceptible to fractures, especially in postmenopausal women already at risk due to estrogen deficiency )Chen et al.,2020).

         Estrogen and vitamin D deficiencies can interact synergistically to accelerate bone loss. Estrogen deficiency enhances bone resorption, while vitamin D deficiency impairs calcium absorption and bone mineralization. Together, these factors contribute to significant bone density loss as well as structural integrity. The combined effect of estrogen also vitamin D deficiencies increased the osteoporosis risk also fractures in menopausal women. This risk is particularly pronounced in postmenopausal women because they often experience both deficiencies simultaneously(Seijo et al.,2022 ).

Conclusions

In conclusion, complex interactions between hormones, especially estrogen, testosterone, parathyroid hormone, cortisol, thyroid hormone, and osteoster hormone, affect bone health and the progression of osteoporosis These hormones play an important role in bone consolidation, resorption, and formation throughout the lifespan. Imbalances or deficiencies of these hormones, due to natural aging, medical conditions, or external factors, can impair bone regeneration, and increase osteoporosis and fracture risk the delicate balance Understanding the complex relationship between mutations, vitamin D deficiency, and osteoporosis emphasizes the importance of proactive management and prevention strategies. Vitamin D and calcium supplements, judicious sun exposure, and lifestyle changes for optimal bone health may include In particular, how to manage and ensure hormonal imbalances that adequate levels of vitamin D are an important step in reducing the risk of osteoporosis and its complications, especially menopause. In vulnerable populations such as northern women, a comprehensive approach to bone health can enable individuals to maintain strong, flexible bones throughout their lives.

Acknowledgment

None.

Conflicts of Interest

None.

References

• Aayushi, B., & Kekatpure, A. L. (2022). Postmenopausal Osteoporosis: A Literature Review. Cureus, 14(9).
• Abdullah, M. A., Abdullah, A. H., Alfatlawi, W. R., & Yahya, C. Z. M. (2021). A Comparative Study Of The Levels Osteoproteger In (OPG), Vitamin D, Parathyroid Hormone, And Estrogen Hormone Between Healthy Females And Breast Cancer Patients. NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO, 62-76.
• Abed, M. N., Alassaf, F. A., Qazzaz, M. E., Alfahad, M., & Jasim, M. H. (2020). Insights into the perspective correlation between vitamin D and regulation of hormones: Thyroid and Parathyroid Hormones. Clinical Reviews in Bone and Mineral Metabolism, 18, 87-93.
• Adejuyigbe, B., Kallini, J., Chiou, D., & Kallini, J. R. (2023). Osteoporosis: molecular pathology, diagnostics, and therapeutics. International Journal of Molecular Sciences, 24(19), 14583.
• Ahi, S., Dehdar, M. R., & Hatami, N. (2020). Vitamin D deficiency in non-autoimmune hypothyroidism: a case-control study. BMC endocrine disorders, 20(1), 1-6.
• Ahmadzadeh, K., Vanoppen, M., Rose, C. D., Matthys, P., & Wouters, C. H. (2022). Multinucleated giant cells: current insights in phenotype, biological activities, and mechanism of formation. Frontiers in Cell and Developmental Biology, 10, 873226.
• Al‐Bari, A. A., & Al Mamun, A. (2020). Current advances in regulation of bone homeostasis. Faseb Bioadvances, 2(11), 668.
• Allgrove, J., & Cheung, M. (2019). The parathyroid and disorders of calcium and bone metabolism. Brook’s Clinical Pediatric Endocrinology, 409-479.
• Al-Rawaf, H. A., Alghadir, A. H., & Gabr, S. A. (2021). Circulating MicroRNA expression, vitamin D, and hypercortisolism as predictors of osteoporosis in elderly postmenopausal women. Disease Markers, 2021.
• Al-Suhaimi, E. A. (2022). Bone Remodeling Physiology: Regulation of Parathyroid Glands, C Cells, Vitamin D, and Bone as an Endocrine Organ. In Emerging Concepts in Endocrine Structure and Functions (pp. 161-199). Singapore: Springer Nature Singapore.
• Amin, U., McPartland, A., O’Sullivan, M., & Silke, C. (2023). An overview of the management of osteoporosis in the aging female population. Women’s Health, 19, 17455057231176655.
• Anagnostis, P., Bosdou, J. K., Vaitsi, K., Goulis, D. G., & Lambrinoudaki, I. (2021). Estrogen and bones after menopause: a reappraisal of data and future perspectives. Hormones, 20(1), 13-21.
• Anam, A. K., & Insogna, K. (2021). Update on osteoporosis screening and management. Medical Clinics, 105(6), 1117-1134.
• Anesi, A., Generali, L., Sandoni, L., Pozzi, S., & Grande, A. (2019). From osteoclast differentiation to osteonecrosis of the jaw: molecular and clinical insights. International journal of molecular sciences, 20(19), 4925.
• Askin, M., Koc, E. M., Soyoz, M., Aksun, S., Aydogmus, S., & Sozmen, K. (2019). Relationship between postmenopausal vitamin D level, menopausal symptoms and sexual functions. J Coll Physicians Surg Pak, 29(9), 823-827.
• Aspray, T. J., & Hill, T. R. (2019). Osteoporosis and the ageing skeleton. Biochemistry and cell biology of ageing: Part II clinical science, 453-476.
• Beltz, A. M., & Moser, J. S. (2020). Ovarian hormones: a long overlooked but critical contributor to cognitive brain structures and function. Annals of the New York Academy of Sciences, 1464(1), 156-180.
• Bhattarai, H. K., Shrestha, S., Rokka, K., & Shakya, R. (2020). Vitamin D, calcium, parathyroid hormone, and sex steroids in bone health and effects of aging. Journal of osteoporosis, 2020.
• Bolamperti, S., Villa, I., & Rubinacci, A. (2022). Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Research, 10(1), 48.
• Cannarella, R., Barbagallo, F., Condorelli, R. A., Aversa, A., La Vignera, S., & Calogero, A. E. (2019). Osteoporosis from an endocrine perspective: the role of hormonal changes in the elderly. Journal of clinical medicine, 8(10), 1564.
• Chandra, A., & Rajawat, J. (2021). Skeletal aging and osteoporosis: mechanisms and therapeutics. International journal of molecular sciences, 22(7), 3553.
• Chang, Y., Cho, B., Kim, S., & Kim, J. (2019). Direct conversion of fibroblasts to osteoblasts as a novel strategy for bone regeneration in elderly individuals. Experimental & Molecular Medicine, 51(5), 1-8.
• Charoenngam, N., Shirvani, A., & Holick, M. F. (2019). Vitamin D for skeletal and non-skeletal health: What we should know. Journal of clinical orthopaedics and trauma, 10(6), 1082-1093.
• Chen, C. L., Chen, N. C., Wu, F. Z., & Wu, M. T. (2020). Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporosis International, 31, 1507-1516.
• Cheng, C. H., Chen, L. R., & Chen, K. H. (2022). Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. International Journal of Molecular Sciences, 23(3), 1376.
• Christakos, S., Li, S., De La Cruz, J., Shroyer, N. F., Criss, Z. K., Verzi, M. P., & Fleet, J. C. (2020). Vitamin D and the intestine: Review and update. The Journal of steroid biochemistry and molecular biology, 196, 105501.
• De Martinis, M., Allegra, A., Sirufo, M. M., Tonacci, A., Pioggia, G., Raggiunti, M., … & Gangemi, S. (2021). Vitamin D deficiency, osteoporosis and effect on autoimmune diseases and hematopoiesis: a review. International journal of molecular sciences, 22(16), 8855.
• DeLuccia, R., Clegg, D., & Sukumar, D. (2021). The implications of vitamin D deficiency on COVID-19 for at-risk populations. Nutrition reviews, 79(2), 227-234.
• Di Bari, F., Catalano, A., Bellone, F., Martino, G., & Benvenga, S. (2021). Vitamin D, bone metabolism, and fracture risk in polycystic ovary syndrome. Metabolites, 11(2), 116.
• Dominguez, L. J., Farruggia, M., Veronese, N., & Barbagallo, M. (2021). Vitamin D sources, metabolism, and deficiency: available compounds and guidelines for its treatment. Metabolites, 11(4), 255.
• Eirini, K., Nikolaos, T., Papadopoulou, S. K., & Georgios, G. (2022). Bone Density Measurements and Biomarkers in Nutrition: DXA (Dual X-ray Absorptiometry), Osteopenia, and Osteoporosis. In Biomarkers in Nutrition (pp. 1067-1084). Cham: Springer International Publishing.
• Eltayef, M. (2022). Osteoprotegerin, Parathyroid Hormone and Vitamin D as Effective Factors on Serum-Urine Calcium Levels in Breast Cancer Patients. Archives of Razi Institute, 77(5), 1975.
• Enitan, S. S., Adejumo, B. I. G., & Adejumo, E. N. (2023). Empowering women to combat osteoporosis: unveiling the causes, consequences, and control strategies. Aging Commun, 5(3), 13.
• Ferrillo, M., Migliario, M., Marotta, N., Lippi, L., Antonelli, A., Calafiore, D., … & de Sire, A. (2022). Oral health in breast cancer women with vitamin D deficiency: A machine learning study. Journal of Clinical Medicine, 11(16), 4662.
• Fleet, J. C. (2022). Vitamin D-mediated regulation of intestinal calcium absorption. Nutrients, 14(16), 3351.
• Gosset, A., Pouillès, J. M., & Trémollieres, F. (2021). Menopausal hormone therapy for the management of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism, 35(6), 101551.
• Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J., … & Compston, J. (2022). UK clinical guideline for the prevention and treatment of osteoporosis. Archives of osteoporosis, 17(1), 58.
• Hadji, P., Colli, E., & Regidor, P. A. (2019). Bone health in estrogen-free contraception. Osteoporosis International, 30(12), 2391-2400.
• Hassan, N. E., El Shebini, S. M., El-Masry, S. A., Ahmed, N. H., Eldeen, G. N., Rasheed, E. A., … & Khalil, A. (2021). Association of some dietary ingredients, vitamin D, estrogen, and obesity polymorphic receptor genes with bone mineral density in a sample of obese Egyptian women. Journal of Genetic Engineering and Biotechnology, 19(1), 28.
• Hejazi, J., Davoodi, A., Khosravi, M., Sedaghat, M., Abedi, V., Hosseinverdi, S., … & Shojaie, L. (2020). Nutrition and osteoporosis prevention and treatment. Biomedical research and Therapy, 7(4), 3709-3720.
• Huang, H., Guo, J., Chen, Q., Chen, X., Yang, Y., Zhang, W., … & Yang, D. (2019). The synergistic effects of vitamin D and estradiol deficiency on metabolic syndrome in Chinese postmenopausal women. Menopause, 26(10), 1171-1177.
• Ito, E., Sato, Y., Kobayashi, T., Nakamura, S., Kaneko, Y., Soma, T., … & Miyamoto, T. (2021). Treatment with an active vitamin D analogue blocks hypothalamic dysfunction-induced bone loss in mice. Biochemical and Biophysical Research Communications, 542, 48-53.
• Jou, P. C., & Tomecki, K. J. (2014). Sunscreens in the United States: current status and future outlook. Advances in experimental medicine and biology, 810, 464-484.
• Jubair, S., Nsaif, A. S., Abdullah, A. H., & Dhefer, I. H. (2021). Vitamin D deficiency is associated with thyroid diseases. In Journal of Physics: Conference Series (Vol. 1853, No. 1, p. 012036). IOP Publishing.
• Keogh, J. B., & Clifton, P. M. (2013). Vitamin D and cardiovascular health. Current Opinion in Lipidology, 24(2), 183-184.
• Lademann, F., Tsourdi, E., Hofbauer, L. C., & Rauner, M. (2020). Thyroid hormone actions and bone remodeling–the role of the wnt signaling pathway. Experimental and Clinical Endocrinology & Diabetes, 128(06/07), 450-454.
• Lewis, J. (2022). Characterising the therapeutic potential of PEPITEMin age-related bone loss, skeletal remodelling and repair (Doctoral dissertation, University of Birmingham).
• Lombardi, G., Ziemann, E., Banfi, G., & Corbetta, S. (2020). Physical activity-dependent regulation of parathyroid hormone and calcium-phosphorous metabolism. International journal of molecular sciences, 21(15), 5388.
• Lu, L., & Tian, L. (2023). Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen. Journal of Endocrinology, 259(1).
• Marozik, P., Rudenka, A., Kobets, K., & Rudenka, E. (2021). Vitamin D status, bone mineral density, and VDR gene polymorphism in a cohort of Belarusian postmenopausal women. Nutrients, 13(3), 837.
• Mazziotti, G., Lania, A. G., & Canalis, E. (2022). Skeletal disorders associated with the growth hormone–insulin-like growth factor 1 axis. Nature Reviews Endocrinology, 18(6), 353-365.
• Mizoguchi, T., & Ono, N. (2020). The diverse origin of bone‐forming osteoblasts. Journal of Bone and Mineral Research, 36(8), 1432-1447.
• Perugini, P., Bonetti, M., Cozzi, A. C., & Colombo, G. L. (2019). Topical sunscreen application preventing skin cancer: systematic review. Cosmetics, 6(3), 42.
• Pignolo, R. J., Law, S. F., & Chandra, A. (2021). Bone aging, cellular senescence, and osteoporosis. Journal of Bone and Mineral Research Plus, 5(4), e10488.
• Pinheiro, M. B., Oliveira, J., Bauman, A., Fairhall, N., Kwok, W., & Sherrington, C. (2020). Evidence on physical activity and osteoporosis prevention for people aged 65+ years: a systematic review to inform the WHO guidelines on physical activity and sedentary behaviour. International Journal of Behavioral Nutrition and Physical Activity, 17, 1-53.
• Ponzano, M., Tibert, N., Brien, S., Funnell, L., Gibbs, J. C., Keller, H., … & Giangregorio, L. M. (2023). International consensus on the non-pharmacological and non-surgical management of osteoporotic vertebral fractures. Osteoporosis International, 34(6), 1065-1074.
• Rinonapoli, G., Ruggiero, C., Meccariello, L., Bisaccia, M., Ceccarini, P., & Caraffa, A. (2021). Osteoporosis in men: a review of an underestimated bone condition. International journal of molecular sciences, 22(4), 2105.
• Rizzoli, R., & Biver, E. (2020). Are probiotics the new calcium and vitamin D for bone health?. Current osteoporosis reports, 18, 273-284.
• Roy, K. (2021). Osteoporosis: A Silent Life Threatening Disease: Osteoporosis: A Silent Life Threatening Disease. Indian Journal of Physiology and Allied Sciences, 73(1).
• Rozenberg, S., Bruyère, O., Bergmann, P., Cavalier, E., Gielen, E., Goemaere, S., … & Body, J. J. (2020). How to manage osteoporosis before the age of 50. Maturitas, 138, 14-25.
• Rozenberg, S., Bruyère, O., Bergmann, P., Cavalier, E., Gielen, E., Goemaere, S., … & Body, J. J. (2020). How to manage osteoporosis before the age of 50. Maturitas, 138, 14-25..
• Seijo, M., Bonanno, M. N., Bryk, G., Zeni Coronel, M. E., Pita Martin de Portela, M. L., & Zeni, S. N. (2022). Does vitamin D insufficiency influence prebiotic effect on calcium absorption and bone retention?. Calcified Tissue International, 111(3), 300-312.
• Setiawati, R., & Rahardjo, P. (2019). Bone development and growth. Osteogenesis and bone regeneration, 10.
• Sharma, A., Sharma, L., & Goyal, R. (2021). Molecular signaling pathways and essential metabolic elements in bone remodeling: An implication of therapeutic targets for bone diseases. Current Drug Targets, 22(1), 77-104.
• Shigehara, K., Izumi, K., Kadono, Y., & Mizokami, A. (2021). Testosterone and bone health in men: a narrative review. Journal of Clinical Medicine, 10(3), 530.
• Sims, N. A., & Martin, T. J. (2020). Osteoclasts provide coupling signals to osteoblast lineage cells through multiple mechanisms. Annual review of physiology, 82, 507-529.
• Sobh, M. M., Abdalbary, M., Elnagar, S., Nagy, E., Elshabrawy, N., Abdelsalam, M., … & El-Husseini, A. (2022). Secondary osteoporosis and metabolic bone diseases. Journal of Clinical Medicine, 11(9), 2382.
• Søe, K., Delaisse, J. M., & Borggaard, X. G. (2021). Osteoclast formation at the bone marrow/bone surface interface: Importance of structural elements, matrix, and intercellular communication. In Seminars in Cell & Developmental Biology (Vol. 112, pp. 8-15). Academic Press.
• Srinivasan, A., Wong, F. K., & Karponis, D. (2020). Calcitonin: A useful old friend. Journal of musculoskeletal & neuronal interactions, 20(4), 600.
• Takito, J., & Nakamura, M. (2020). Heterogeneity and actin cytoskeleton in osteoclast and macrophage multinucleation. International Journal of Molecular Sciences, 21(18), 6629.
• Toosi, S., & Behravan, J. (2020). Osteogenesis and bone remodeling: A focus on growth factors and bioactive peptides. Biofactors, 46(3), 326-340.
• Tremollieres, F. (2019). Assessment and hormonal management of osteoporosis. Climacteric, 22(2), 122-126.
• van Driel, M., & van Leeuwen, J. P. (2023). Vitamin D and bone: a story of endocrine and auto/paracrine action in osteoblasts. Nutrients, 15(3), 480.
• Vescini, F., Chiodini, I., Falchetti, A., Palermo, A., Salcuni, A. S., Bonadonna, S., … & Gennari, L. (2021). Management of osteoporosis in men: a narrative review. International journal of molecular sciences, 22(24), 13640.
• Wawrzyniak, N., & Suliburska, J. (2021). Nutritional and health factors affecting the bioavailability of calcium: a narrative review. Nutrition Reviews, 79(12), 1307-1320.
• Wu, J. C., Strickland, C. D., & Chambers, J. S. (2019). Wrist fractures and osteoporosis. Orthopedic Clinics, 50(2), 211-221.
• Xue, S., Kemal, O., Lu, M., Lix, L. M., Leslie, W. D., & Yang, S. (2020). Age at attainment of peak bone mineral density and its associated factors: The National Health and Nutrition Examination Survey 2005–2014. Bone, 131, 115163.